PX13-R + Eloralintide — Research Overview
PX13-R + Eloralintide is an advanced lyophilized research blend that combines PX13-R, a triple agonist compound, with Eloralintide in a single vial for laboratory research into combined metabolic pathways. Manufactured in America and independently tested for identity and purity.
Supplied as a research-grade compound for in-vitro and laboratory investigation.
Research classification and format
PX13-R + Eloralintide is classified on this page as a research peptide and is supplied in a lyophilized research preparation. The presentation is intended to support controlled laboratory workflows, analytical method development, and documented preclinical or in-vitro investigation appropriate to the compound.
PX1 quality and documentation
PX1 Research manufactures and finishes this product in American GMP laboratories rather than purchasing finished vials from overseas. Each released lot is evaluated through the PX1 quality program, with identity, purity, appearance, and applicable contaminant or endotoxin results documented on the lot-linked Certificate of Analysis. Researchers should review the current COA and Safety Data Sheet shown on this page before beginning work.
Laboratory handling
Store the sealed preparation at −20°C for long-term stability and protect it from light. Bring the closed vial to room temperature before opening, follow the laboratory's validated preparation protocol, and minimize repeated freeze–thaw cycles. Use calibrated equipment, document concentration and storage conditions, and follow institutional safety procedures throughout the study.
Intended use
For research use only. Not for human or veterinary use, consumption, diagnosis, treatment, or medical application. This material should be handled only by qualified professionals in an appropriate laboratory setting.